Recent research have converged on the intersection of GLP-1|GIP|GCGR stimulant therapies and dopamine neurotransmission. While GCGR agonists are increasingly employed for addressing type 2 diabetes, their emerging effects on motivation circuits, specifically governed by dopamine pathways, are gaining considerable attention. This paper presents a… Read More